Wedbush reaffirmed their neutral rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $10.00 price target on the technology company’s stock. A number of other research analysts have also commented on the company. Leerink Partnrs reiterated an outperform rating on shares […]

Related Keywords

China , Leerink Partnrs , Robertw Baird , Cogent Biosciences Inc , Dynamic Technology Lab Private Ltd , Investment Management , China Universal Asset Management Co , Needham Company , Russell Investments Group Ltd , Jpmorgan Chase Co , Cogent Biosciences , Free Report , Moderate Buy , Get Free Report , Universal Asset Management , Investments Group , Technology Lab Private Ltd , Cogent Biosciences Daily ,